Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

Share Price is delayed by 15 minutes
Get Live Data
503.50    -1.50 (-0.30%)
Bid:
503.50
Ask:
505.50
Spread: 2.00 (0.397%)
Market Cap: £2.23b
TATE Live PriceLast checked at - London Stock Exchange

Intraday Tate & Lyle Share Chart

Trading Statement

25 Jul 2024 07:00

RNS Number : 7319X
Tate & Lyle PLC
25 July 2024
Β 

Β 

25 July 2024 - Tate & Lyle PLC

Β 

AGM STATEMENT AND TRADING UPDATE

Β 

Tate & Lyle PLC ('Tate & Lyle', 'the Group') will be holding its Annual General Meeting in London later today. In his address to shareholders, Chief Executive Nick Hampton will comment:

Β 

"We have made a good start to the new financial year with trading in line with our expectations. It's encouraging to see volume momentum across the business, and we continue to expect volume growth to accelerate as the 2025 financial year progresses. Planning for the integration of Tate & Lyle and CP Kelco is progressing well with both organisations excited about the opportunity to deliver significantly greater value for customers and the growth potential of the combined business. We look forward to the future with confidence."

Β 

Trading update for the three months ended 30 June 2024

Β· Group performance in line with our expectations:

- Food & Beverage Solutions volume, as anticipated, was ahead of the comparative period, with revenue lower reflecting the pass through of input cost deflation.

- Sucralose delivered good revenue growth.

- Group EBITDA ahead of the comparative period.

Β 

Acquisition of CP Kelco

Β· On 20 June 2024, Tate & Lyle entered into an agreement to acquire CP Kelco, a leading provider of pectin, speciality gums and other nature-based ingredients for a total implied consideration of US$1.8 billion (approximately Β£1.4 billion).

Β· This acquisition significantly accelerates Tate & Lyle's strategy as a leading and differentiated speciality food and beverage solutions business, and the solutions partner of choice for customers. The combined business will be a leader in Mouthfeel solutions and will also provide a stronger customer offering across our Sweetening and Fortification platforms, and our four core categories. Further details of the acquisition can be found here.

Β· CP Kelco's financial performance in the first half of the 2024 calendar year has stabilised as anticipated, with volume well ahead of the comparative period.

Β· Following the announcement by the Financial Conduct Authority on 11 July 2024 that the new Listing Rules will come into effect on 29 July 2024, the requirement for a shareholder vote for significant transactions will no longer apply. We intend to comply with the new disclosure requirements for significant transactions that were announced ahead of the rule changes.

Β· Completion of the transaction remains conditional on receipt of regulatory approvals and other customary conditions. We continue to expect this will occur in the fourth quarter of the 2024 calendar year.

Β 

Progress on share buyback programme

Β· On 20 June 2024, we commenced a Β£215 million on-market share buyback programme to return the net cash proceeds from the sale of our remaining interest in Primient to shareholders.Β 

Β· As at the close of business on 24 July 2024, a total of 6.7 million shares have been purchased under this programme for a cost of Β£42 million and are being held as treasury shares.

Β 

Outlook for year ending 31 March 2025 is unchanged (for standalone Tate & Lyle, excluding CP Kelco)

Β· We continue to expect to deliver in constant currency:

- Revenue slightly lower than the prior year

- EBITDA growth of between 4% and 7%.

Β 

END

Β 

Β 

For more information contact Tate & Lyle PLC:

Christopher Marsh, VP, Investor Relations

Mobile: +44 (0) 7796 192 688

Β 

Media

Nick Hasell, FTI Consulting

Tel: Mobile: +44 (0) 7825 523 383

Tel: Office: +44 (0) 203 727 1340

tate@fticonsulting.com

Β 

Β 

About Tate & Lyle:

Β 

Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day. Through our expertise in sweetening, fortification, and texture, we develop ingredient solutions which reduce sugar, calories, and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

Β 

We have more than 3,300 employees working in around 58 locations serving customers across

121 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives Through the Science of Food. By living our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Β 

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2024, Tate & Lyle revenue from continuing operations totalled Β£1.65 billion.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTQKQBBOBKDAOB
Date   Source Headline
27th May 20217:00 amRNSFinal Results
4th May 202111:30 amRNSTotal Voting Rights
28th Apr 202110:00 amRNSDirectorate Change
26th Apr 20217:00 amRNSResponse to media speculation
13th Apr 20213:45 pmRNSHolding(s) in Company
1st Apr 202112:00 pmRNSTotal Voting Rights
25th Mar 202110:00 amRNSDirectorate Changes
23rd Mar 20213:00 pmRNSHolding(s) in Company
12th Mar 202111:00 amRNSDirector Declaration
1st Mar 202111:00 amRNSTotal Voting Rights
26th Feb 202111:00 amRNSDirector Declaration
15th Feb 20214:43 pmRNSHolding(s) in Company
15th Feb 20214:40 pmRNSHolding(s) in Company
15th Feb 20214:37 pmRNSHolding(s) in Company
10th Feb 202111:15 amRNSAcquisition
28th Jan 20217:00 amRNSTrading Statement
21st Jan 20217:00 amRNSVivid Sehgal Appointed Chief Financial Officer
12th Jan 20213:30 pmRNSDirector/PDMR Shareholding
4th Jan 20213:05 pmRNSBlock listing Interim Review
4th Jan 20213:04 pmRNSTotal Voting Rights
30th Dec 20201:00 pmRNSBoard Changes
7th Dec 202011:06 amRNSDirector/PDMR Shareholding
1st Dec 20207:00 amRNSTATE & LYLE ACQUIRES SWEET GREEN FIELDS
5th Nov 20207:00 amRNSHalf-year Report
28th Oct 20207:00 amRNSTate & Lyle to acquire tapioca business
14th Oct 202011:00 amRNSDirector Declaration
7th Oct 20207:00 amRNSDirectorate Change
2nd Oct 202011:55 amRNSDirector/PDMR Shareholding
1st Oct 20202:30 pmRNSTotal Voting Rights
17th Sep 20207:30 amRNSBlock Listing
8th Sep 202010:00 amRNSDirector/PDMR Shareholding
1st Sep 202012:00 pmRNSTotal Voting Rights
5th Aug 20204:30 pmRNSDirector/PDMR Shareholding
3rd Aug 20202:00 pmRNSTotal Voting Rights
23rd Jul 20201:00 pmRNSResult of AGM
23rd Jul 20207:00 amRNSTrading Statement
2nd Jul 20205:45 pmRNSBlock listing Interim Review
1st Jul 20203:06 pmRNSRights attaching to the listed share capital
1st Jul 20203:05 pmRNSTotal Voting Rights
9th Jun 20203:00 pmRNSAnnual Financial Report
2nd Jun 20203:56 pmRNSDirector/PDMR Shareholding
21st May 20207:00 amRNSFinal Results
4th May 20207:00 amRNSTrading Update
1st May 20203:27 pmRNSTotal Voting Rights
3rd Apr 202011:00 amRNSDirector Declaration
1st Apr 202012:26 pmRNSTotal Voting Rights
6th Feb 20207:00 amRNSTrading Statement
30th Jan 202011:45 amRNSDirector/PDMR Shareholding
7th Jan 20202:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202012:41 pmRNSBlock listing Interim Review

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.